57 yo male, very high muscular/aerobic fitness, one meal a day, strict plant based ketogenic diet for last 6 years, high daily exerciser, TRT, 8 week regular blood donation
No metabolic response to oral rapamycin dosing, deep dive rapamycin literature, exploring alternate drug delivery routes/formulations for superior AUC/mTOR inhibition/lesser side effects profile
6 week update, weekly dosing of a novel human rapamycin drug delivery protocol
Experimentation with Intramuscular (IM) rapamycin (rapamycin powder at 30mg/mL in DSMO) @ 15mg/week
Experimentation with Intranasal (IN) rapamycin (rapamycin powder at 30mg/mL in DSM) @ 3mg/nasal cavity/week
IM + IN delivered 10X AUC of 15mg ORAL and 20X AUC of 6mg/week ORAL
Elevation in TG (TC, LDL, HDL same/lower), slight increase FG, hbA1c, no low WBC counts
Crossover into clinical iron deficiency anemia (but largely manifested by long term chronic phlebotomy as a targeted low level iron store management, a separate n=1 protocol). High dose rapamycin appears to have induced the crossover.
NO SIGNIFICANT SYMPTOMATIC SIDE EFFECTS (100% normal daily activities, including continued daily high resistance/aerobic protocol)
Short term, high dose parenteral rapamycin is unsurprisingly quite safe
Ongoing dosing protocol for metabolic/side effects impact discovery with longer intervention looking for side effects, CBC dysregulation, and any transiency in markers Ć Is bypassing 1st pass metabolism/liver gene expression of oral rapamycin delivery with a fundamentally parenteral IM + IN drug delivery leading to a new āparadigmā of higher pan tissue rapamycin penetration (including brain) and lower side effects (symptomatic and biomarker) equating to a much higher lifespan extension mTOR inhibition translation in humans?
Full Paper below (note - some of the images are best viewed in the Google Docs / Google Drive version above):
Current IM + IN for a while longer, I need to tease out any transiency, good or bad. Iād like to find an upper limit where things go really south and then re-assess.
No. Iāve never taken a tablet of any sort, only powder.
I just finished a first read through though will need to revisit several parts. A very impressive document that deserves to be pinned on the homepage? @RapAdmin
I agreeā¦ as always, @Mac is great at pulling really good information together and presenting it in a compelling wayā¦ the only challenge I have is that it takes significant time for me to sit down and study what heās written - as is definitely the case here.
Iāve pinned it for a month to give us a chance to read, digest and discuss it. I think this is an important area - optimizing dosing strategies across different types of rapalogs, with different dosing schedules and modalities seems like it could be an important approach to maximizing benefits from rapalogs / rapamycin.
Nice job MAC. Bravo for your willingness to step out of the box and try something very different.
Itās very convincing that significant blood levels can be achieved by bypassing the GI tract . This is important since there is so much inter person variability with the oral route.
From a practical viewpoint, many people would want the liquid rapamycin for injection to be pre- made, and yet others wouldnāt like to give themselves shots, so an intranasal formulation might be more compliant friendly.
Iām also curious to know how blood levels would look using a much lower dose, like maybe 3 mgās.
Yes - Iāve done work in Biotech and the market opportunity for small molecule drugs (orally taken) is vastly larger than injection drugsā¦ people generally really shy away from injections unless they absolutely have to have them (think insulin).
Has there ever even been a āblockbusterā drug that was injection? I donāt think so, but I may be wrong.
Though - perhaps that is changing tooā¦ Given the popularity of all these IV drips for vitamins, and clinics (rather scammy clinics in my opinion, due to lack of efficacy data) focused on selling NMN injections, etc. - people seem to be overcoming their reluctance for injections and needles given the right longevity incentives. In the Tim Ferris / Matt K. discussion Tim suggested NMN IV drips are all the rage in Austinā¦ but then again, monthly or irregular iv drips are perhaps different from regular daily or weekly rapamycin injections, from a risk/reward perception standpoint.
I think Iām probably representative here. Iām fine with needles for vaccines, and blood donations, but I havenāt had a needle in my body outside of those use cases in perhaps 30 years.
Future experiment. Will have to washout first, then just do IN. I think IN is fraught with large reproducibility issues given such a VERY small olfactory window with hydrophobic, relatively large molecule rapamycin, so I might have to OVER dose to make sure I get a large signal, and then dial back.
I will certainly update should I run this experiment, it would be worthwhile.
I most interested in longevityā¦will do anything and overcome any impediment. Biology does not care what I think, nor does the clock, or mischievious cancer cells.
I totally get itā¦ whatever works effectively and efficientlyā¦ and long term I think thats the best approach, Iām just a late adopter when it comes to anything injection oriented.
MAC, thanks so much for freely sharing your research and novel protocol with us. Not only am I really impressed with the research you conducted but also how you went beyond the conventional, unquestioned oral dosing protocol and developed and self-administered a radical new approach. If this website would give rankings for members, I think yours should be āNext Level Rapanautā
Iāve only spent a couple of hours so far going over your paper and intend to review it more thoroughly over the next week or two. Here some of my initial reactions and observations as I myself struggle to find the best dosing protocol.
Your AUC on page 55 looks like you took the equivalent of about a 100 mg oral dose of rapamycin! See image below for reference. Kind of makes sense since RAPA is 15% bioavailable and you injected about 15mg. The side effects of this āoverdoseā appeared fairly mild in the patient that took to 103 mg oral RAPA. āPatient 3 complained of tiredness and showed a spontaneous decline in total cholesterol levels several days after overdose which implied that overdose was associated with an elevation in total cholesterol. Triglyceride concentrations were not above the normal range and did not change significantly from day 4 to day 67 post-overdose.ā Maybe if this patient were in better health her side effects would have been less severe.
However, based on the article on the second page of your paper, it appears maximum benefits would be achieved by flattening out the curve and have CMAX = Trough.
āIt is interesting to consider the observation that continuous delivery of rapamycin provided the most effective in vivo treatment regimen. This finding is similar to what has been observed with other known antiangiogenic agents, where low-level continuous-delivery methods induce the greatest anti-tumor effect.ā
This kind of flies in the face of pulsed dosing period, and is making me consider daily dosing. I really like the idea of intranasal dosing throughout the day instead of oral dosing because all the things that inhibit the CYP34a enzyme ā grapefruit, pepper, green tea, parsley ā that can make it near impossible to achieve constant RAPA blood levels. Plus I think you are onto something with bypassing the liver and some of the associated side effects rather then them all being associated with MTOR2 inhibition.
Anyway, this paper is a treasure trove of research and ideas and I canāt thank you enough for all your hard work and generosity. I look forward to reviewing it further and sharing ideas!
āItās very convincing that significant blood levels can be achieved by bypassing the GI tract . This is important since there is so much inter person variability with the oral route.ā
But are we sure that changes in the GI tract brought about by Rapamycin donāt play a role in its systemic effects? Some studies do indicate that, and among others changes in the intestinal microbiome as a result of oral Rapamycin intake have been discussed in research. It is a macrolide antibiotic after all.
